ATE438096T1 - Hla-e bindung zu cd94/nkg2+ zellen - Google Patents

Hla-e bindung zu cd94/nkg2+ zellen

Info

Publication number
ATE438096T1
ATE438096T1 AT98959027T AT98959027T ATE438096T1 AT E438096 T1 ATE438096 T1 AT E438096T1 AT 98959027 T AT98959027 T AT 98959027T AT 98959027 T AT98959027 T AT 98959027T AT E438096 T1 ATE438096 T1 AT E438096T1
Authority
AT
Austria
Prior art keywords
cells
nkg2
hla
binding
inactivation
Prior art date
Application number
AT98959027T
Other languages
English (en)
Inventor
Veronique Braud
David Allan
Graham Ogg
Christopher O'callaghan
Andrew Mcmichael
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE438096T1 publication Critical patent/ATE438096T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
AT98959027T 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen ATE438096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding

Publications (1)

Publication Number Publication Date
ATE438096T1 true ATE438096T1 (de) 2009-08-15

Family

ID=10823165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959027T ATE438096T1 (de) 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen

Country Status (7)

Country Link
US (3) US7410767B1 (de)
EP (2) EP1036327B1 (de)
JP (4) JP4336451B2 (de)
AT (1) ATE438096T1 (de)
DE (1) DE69841020D1 (de)
GB (1) GB9725764D0 (de)
WO (1) WO1999028748A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1423140A2 (de) * 2001-07-31 2004-06-02 Karl Petter Söderström Zusammensetzungen und methode zur modulierung der immunoantwort
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
DE602004016004D1 (de) * 2003-08-26 2008-10-02 Univ Danmarks Tekniske Kontinuierliches verfahren zur anordnung von makromolekulären substanzen und die anschliessende aufnahme und isolierung einer makromolekulären anordnung, sowie ein für dieses verfahren geeignetes system
JP2007536522A (ja) * 2004-05-07 2007-12-13 ベックマン コールター インコーポレーティッド Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
EP2226332A1 (de) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium-tuberculosis-Epitope und Verfahren zu deren Verwendung
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
EP2035452B1 (de) * 2006-06-22 2012-04-25 Novo Nordisk A/S Lösliche heterodimere rezeptoren und ihre verwendung
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
KR20100110864A (ko) 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
KR102047248B1 (ko) 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
WO2014037422A1 (en) 2012-09-04 2014-03-13 Inven2 As Selective and controlled expansion of educated nk cells
US20150037304A1 (en) * 2013-03-12 2015-02-05 Sangamo Biosciences, Inc. Methods and compositions for modification of hla
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3087101B1 (de) 2013-12-20 2024-06-05 Novartis AG Regulierbarer chimärer antigenrezeptor
ES2857226T3 (es) * 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
US10857219B2 (en) * 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
AU2015316991B2 (en) 2014-09-16 2021-04-01 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
EP3573997A4 (de) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. Verfahren und zusammensetzungen zum targeting eines komplexes, der nicht klassisches hla-i und neoantigen umfasst, bei krebs
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3749685A4 (de) * 2018-02-09 2021-12-22 National University of Singapore Aktivierung von chimären nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
WO2019175182A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
EP3539552A1 (de) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Aktivierung und expansion von nkg2c+-nk-zellen
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (de) 2018-08-29 2022-08-17 National University of Singapore Verfahren zur spezifischen stimulation des überlebens und der expansion von genetisch modifizierten immunzellen
CN113316590B (zh) 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
MX2021006194A (es) * 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
EP3773918A4 (de) 2019-03-05 2022-01-05 Nkarta, Inc. Cd19-gerichtete chimäre antigenrezeptoren und deren verwendungen in der immuntherapie
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
KR20230104611A (ko) 2020-09-30 2023-07-10 드렌 바이오, 인크. 항-cd94 항체 및 이의 사용 방법
EP4388012A4 (de) * 2021-08-20 2025-09-17 Univ Duke Auf hla-e-wirt-peptidkomplexe gerichtete antikörper und verwendungen davon
CN120019146A (zh) * 2022-08-11 2025-05-16 宾夕法尼亚大学理事会 通用t细胞和组合物及它们的使用方法
EP4688859A1 (de) * 2023-03-24 2026-02-11 Duke University Auf hla-e-wirt-peptidkomplexe gerichtete antikörper und verwendungen davon
WO2026016730A1 (zh) * 2024-07-17 2026-01-22 广州瑞风生物科技股份有限公司 一种突变hla-e重链、hla-e三聚体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112487A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112485A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
US20080274475A1 (en) 2008-11-06
EP1036327B1 (de) 2009-07-29
JP4336451B2 (ja) 2009-09-30
EP2144065A1 (de) 2010-01-13
WO1999028748A3 (en) 1999-12-23
JP2002513541A (ja) 2002-05-14
JP5268828B2 (ja) 2013-08-21
DE69841020D1 (de) 2009-09-10
JP4437160B2 (ja) 2010-03-24
EP1036327A2 (de) 2000-09-20
GB9725764D0 (en) 1998-02-04
WO1999028748A2 (en) 1999-06-10
JP2013081478A (ja) 2013-05-09
JP2010024233A (ja) 2010-02-04
JP2009106299A (ja) 2009-05-21
US20150361180A1 (en) 2015-12-17
US7410767B1 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
ATE438096T1 (de) Hla-e bindung zu cd94/nkg2+ zellen
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
DE3786407D1 (de) Nukleierungssystem fuer polyamide.
DE69728758D1 (de) Vorrichtung zur kopplung von übertragungselementen
PL363314A1 (en) Energy drag chain
EP1104303A4 (de) Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen
DE69801898D1 (de) Vorrichtung zur isolierung von lastschwingungen
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
DK0755370T3 (da) Insekticide gødningsblandinger
BR9804676A (pt) Processo para o teste de um dispositivo de embreagem automatizado.
AR015687A2 (es) Gen aislado que codifica acil transferasa
DK1082373T3 (da) Klæbemiddelsystem
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DE69713222D1 (de) Fluidenthaltende, schwingungsisolierende Vorrichtung
EA199900950A1 (ru) Маркер для отбора
DE69625230D1 (de) Thrombininhibitoren
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
BG100248A (bg) Инхибитори на скваленсинтетаза
ES2123641T3 (es) Secuencias de acidos nucleicos que codifican o que son complementarias a secuencias de acidos nucleicos que codifican para el receptor de la interleucina 9.
BR9712532A (pt) Método para aumentar o nìvel de expressão de um transgene população de células monocotiledÈneas,plantas e sementes
ES2171549T3 (es) Or-1 en receptor huerfano perteneciente a la familia de receptores nucleares.
PE20399A1 (es) Muteina ob
ATE239369T1 (de) Vorrichtung zum vertreiben von schädlingen
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
DE69931723D1 (de) Vorrichtung zur Dämpfung von Drehmomentschwankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties